| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel |
| Brand | Duodopa® |
| Indication | For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted. |
| Assessment Process | |
| Rapid review commissioned | 13/03/2013 |
| Rapid review completed | 16/04/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/06/2018 |
| Pre-submission consultation with Applicant | 05/07/2018 |
| Full submission received from Applicant | 10/09/2018 |
| Preliminary review sent to Applicant | 05/12/2018 |
| NCPE assessment re-commenced | 14/01/2019 |
| Follow-up to preliminary review sent to Applicant | 30/01/2019 |
| NCPE assessment re-commenced | 15/02/2019 |
| Factual accuracy sent to Applicant | 19/03/2019 |
| NCPE assessment re-commenced | 02/04/2019 |
| NCPE assessment completed | 14/06/2019 |
| NCPE assessment outcome | The NCPE recommends that levodopa and carbidopa intestinal gel (Duodopa®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.